Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy

J. Nemunaitis, J. W. Singer, C. D. Buckner, T. Mori, J. Laponi, R. Hill, R. Storb, K. M. Sullivan, J. A. Hansen, F. R. Appelbaum

    Research output: Contribution to journalArticlepeer-review

    15 Scopus citations

    Abstract

    Twenty-seven patients with lymphoid neoplasia who underwent autologous bone marrow transplant (BMT) and who had received recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) were followed in order to examine the potential long-term consequences of rhGM-CSF. rhGM-CSF (15-240 μg/m2/day) was given daily either for 14 or 21 days after marrow infusion. All surviving patients who remained in remission had stable marrow graft function. The actuarial survival rate was 45% and the relapse incidence was 50% at a median of 774 days after autologous BMT. These findings suggest that treatment with rhGM-CSF does not have profound adverse long-term consequences.

    Original languageEnglish (US)
    Pages (from-to)49-52
    Number of pages4
    JournalBone marrow transplantation
    Volume7
    Issue number1
    StatePublished - 1991

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Fingerprint

    Dive into the research topics of 'Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy'. Together they form a unique fingerprint.

    Cite this